key: cord-0955174-mnym60ff
authors: Storti, P.; Marchica, V.; Vescovini, R.; Franceschi, V.; Russo, L.; Raimondi, V.; Toscani, D.; Burroughs Garcia, J.; Costa, F.; Dalla Palma, B.; Soressi, N.; Giaimo, M.; Iannozzi, N. T.; Notarfranchi, L.; Sammarelli, G.; Donofrio, G.; Giuliani, N.
title: Impact of Omicron variant on the response to SARS-CoV-2 mRNA vaccination in multiple myeloma and monoclonal gammopathies
date: 2022-02-26
journal: nan
DOI: 10.1101/2022.02.25.22271501
sha: 04ac3a8ad635d97973510848b6b3774c35ab2ff0
doc_id: 955174
cord_uid: mnym60ff

Multiple myeloma (MM) patients may have a reduced response to vaccination due to immunodeficiency. The humoral and cellular response to SARS-CoV-2 mRNA full vaccination and booster dose as well as the impact of spike variants, including the emerging Omicron one, are still unclear and have been investigated in this study in a cohort of MM patients and those with pre-malignant monoclonal gammopathies. Firstly, we have shown that MM patients with relapsed-refractory disease (MMR) had a reduced spike-specific antibody levels and neutralizing titers after SARS-CoV-2 mRNA full vaccination. Interestingly, all the analyzed variants, remarkably Omicron, had a significant negative impact on the neutralizing ability of the vaccine-induced antibodies in all patients with MM and in smoldering MM too. Moreover, lower spike-specific IL-2-producing CD4+ T cells and reduced cytotoxic spike-specific IFN-{gamma} and TNF--producing-CD8+ T cells were found in MM patients as compared to MGUS. Finally, we found that booster immunization improved SARS-CoV-2 spike humoral and cellular responses in newly diagnosed MM (MMD) patients and in most, but not all, MMR patients. After the booster dose, a significant increase of the neutralizing antibody titers against almost all the analyzed variants was achieved in MMD. On the other hand, in MMR patients, Omicron retain a negative impact on neutralizing ability, suggesting these patients need to be considered still at risk of Omicron SARS-CoV-2 infection with a clinically relevant disease.

Multiple myeloma (MM) is a hematological malignancy characterized by impairment of both cellular and humoral responses, 1 with high risk of infection including viral and bacterial ones. 2 Alterations of immune response to infections have been also describe in the pre-malignant state of monoclonal gammopathies as monoclonal gammopathies of undetermined significance (MGUS) and smoldering myeloma (SMM); although the risk of infections in this type of patients is lower as compared to MM patients. [2] [3] [4] The well-known severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic infection completely changed the epidemiological scenario also in hematological patients including MM due to either their intrinsic immunological defects or to the effect of the immunesuppressive treatment. It has been reported that COVID-19 causes moderate to severe acute respiratory disease in approximately 75% to 80% of patients with MM, resulting in death in almost one-third of hospitalized patients. 5, 6 Thus, vaccination against SARS-CoV-2 is the most important preventive strategy to protect MM patients from COVID-19. Published data show that MM patients share a reduced antibody production in response to anti-SARS-CoV-2 vaccination. 7, 8 In addition, MM patients treated with anti-CD38 or anti-B-cell maturation antigen (BCMA) antibodies, seem not to develop anti-SARS-CoV-2 antibodies or have insufficient response even after full vaccination. 9, 10 However, very few data are actually available about the cellular response to SARS-CoV-2 mRNA vaccination 11 and the efficacy of the mRNA vaccine, including the booster dose, to the different SARS-CoV-2 variant characterized by mutations encoding for the spike protein. 12 Since November 2021, the B.1.1.529 (Omicron) variant has rapidly become dominant globally. 13 Omicron partially evades antibodies induced by infection or vaccination and it raises concerns regarding the effectiveness of current vaccines. [14] [15] [16] Few data are available on the response after full vaccination and booster dose in cancer patients 17 and any detailed studies are available in patients with MM and monoclonal gammopathies.

In this study, we investigated both the humoral and cellular response to SARS-CoV-2 mRNA full vaccination and to the booster dose in a cohort of patients with MGUS, SMM and MM. In these All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 26, 2022. ;  https://doi.org/10.1101/2022.02.25.22271501 doi: medRxiv preprint patients, we quantified SARS-CoV-2 spike IgG antibodies (spike-IgG-Abs), neutralizing antibody (NAb) titers against vaccine homologous spike and five variants of concern (VoC), including Omicron, and SARS-CoV-2 spike-specific CD4 + and CD8 + T cells. Moreover, in MM patients we also studied the effect of a booster dose on the SARS-CoV-2 spike-specific immune responses, especially, on the neutralizing capacity against the spike variants. Peripheral blood (PB) samples were collected at two time points: before the first dose (PRE) and 14±2 days after the second dose (POST), i.e 35 days after the first dose of the BNT162b2, mRNA vaccine by Pfizer-BioNTech (Fig 1A) . In a subset of 16 patients with MM (MMD and MMR), blood samples were also collected after 14±2 days of a heterologous booster dose (BOOSTER) with SeroIndex, Kantaro Quantitative SARS-CoV-2 IgG Antibody Kit, R&D Systems), according to the manufacturer's recommendations. Quantitative results are reported in Arbitrary Units/ml (AU/mL) with the lower limit of detection at <3.20 (AU/mL).

Lentiviral vector-based SARS-CoV-2 spike pseudoviruses were generated as previously described 18 with minor modifications as described in Supplemental Data. SARS-CoV-2 spike pseudoviruses displayed on their surface 6 different spike glycoproteins: Wuhan-Hu-1 (B. compared and normalized to those derived from wells where pseudovirus was added in the absence of sera (100%). Neutralization titer 50 (NT50) was expressed as the maximal dilution of the sera where the reduction of the signal is ≥50%. Each serum was tested in triplicate.

Patients' PBMCs were thawed, resuspended in RPMI media supplemented with 10% heat-inactivated fetal calf serum (Biochrom, GmbH), 2 mM L-glutamine and 1% penicillin-streptomycin (R10) and rested at 37 °C for 6h. After resting, 1x10 6 cells of each sample were supplemented with R10 containing CD107a (cat. 555801, BD Pharmingen), monensin (cat.554724, BD Golgi Stop, BD Biosciences) and S1 and S2 peptide pools (PepMIX SARS-CoV-2 spikeglicoprotein, cat. PM-WCPV-S-3, JPT Peptide Techonologies GmbH) added at a final concentration of 1 μg/ml. For each tested sample, a positive control (S. enterotoxin B at 2 μg/ml, Sigma Aldrich) and an unstimulated control (stimulation with an All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

We evaluated spike-IgG-Abs PRE and POST BNT162b2 mRNA vaccination in 40 patients with monoclonal gammopathies at different stages of disease. (Fig. 1A, B) . Two patient were excluded, one because pre-existing antibodies (Fig 1B, orange dots) and the second because having COVID-19 infection between the time points. (Fig 1B, The seropositivity rate for Spike-IgG-Abs in the total cohort was 86.8% (n. 33) with 5 (13.2%) patients exhibiting no detectable antibodies (Fig.1B) . We did not find any significant correlation of the humoral response with patients' age (Suppl. Fig. 2A) . Looking at the different stages of disease, we found that MMR patients had significantly lower spike-IgG-Abs as compared with MGUS, SMM and MMD patients (Fig. 1C) .

Moreover, we found that all 5 seronegative patients had immunoparesis in 2/3 Ig classes and that, overall, the presence of immunoparesis in 2/3 classes was associated with lower spike-IgG-Abs compared to involvement of only 1 class of Ig (Fig. 1D ).

Considering other immune parameters possible affecting the vaccine-induced humoral responses, we did not find any significant correlation between spike-IgG-Abs responses and the baseline (PRE) total lymphocyte counts although they were significantly reduced in MMR and MMD patients compared with MGUS patients (Suppl. Fig. 2B ,C). Interestingly, there was a significant correlation between spike-IgG-Abs and the baseline total CD4 + T cells counts (Fig. 1E ), but not with total CD8 + T cells counts (Fig. 1F ) and with the baseline CD4 + /CD8 + ratio (Fig. 1G ). In line with literature data, we found a significantly reduced CD4 + /CD8 + ratio in MMR and also in MMD compared with the other monoclonal gammopathies. (Suppl. Fig. 2D ).

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in To examine the functional quality of vaccine-induced antibodies, we tested patients' sera using a neutralization assay with a pseudovirus displaying on its surface vaccine homologous spike (Wuhan-Hu-1 sequence). Looking at the different stages of disease, we found that MMR patients had significantly lower NAb titers compared with MGUS, SMM and MMD patients ( Fig. 2A) . Notably, 5 out of 6 patients with a neutralizing titer below the detection level were MMR patients. We found a significant correlation between spike-IgG-Abs levels and neutralizing titers against Wuhan-Hu-1 spike (Fig. 2B ).

We next wanted to determine whether the vaccine-induced antibodies protect patients against VoC of the virus that raise concerns regarding the effectiveness of current vaccines. [19] [20] [21] [22] We tested patients' We analyzed neutralizing titers to the five variants in comparison to Wuhan-Hu-1 spike, in patients stratified for disease stages (Fig. 2H ). Interestingly, among MGUS patients, we found that NAb titers to Beta and Omicron variants were significantly lower than Wuhan-Hu-1 spike. On the contrary, among SMM and MMD patients, NAb titers to all variants were significantly lower than original spike. (Fig. 2H ) In MMR patients, already showing a significant reduction in NAb titers to the Wuhan-Hu-1 spike compared with other patients ( Fig. 2A) , we found lower NAb titers to Beta, Delta and Omicron variants than original spike (Fig. 2H ).

In particular, the neutralization ability against Omicron variant was dramatically reduced in all groups of patients (red dots in Fig.2H ): in MMR patients we did not find any detectable neutralizing titer (0/13) against this variant compared to 4/6 (66.6%), 4/10 (40%), and 3/9 (33.3) in MGUS, SMM and MMD patients, respectively. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in These data overall indicated that, after full vaccination, all the analyzed variants, remarkably the Omicron one, had a significant negative impact on the neutralizing ability of the vaccine-induced antibodies in SMM, MMD and MMR.

Clinical studies have suggested a protective role for both humoral and cell-mediated immunity in recovery from SARS-CoV-2 infection [23] [24] [25] and the goal of COVID-vaccines is to elicit a coordinated immunological memory including both NAbs and SARS-CoV-2 spike-specific T cells. 26 First, we noticed that CD4 + and CD8 + T cell responses to SARS-CoV-2 vaccine were highly variable in our cohort (Fig 3) . We observed that 100% of MGUS patients had a SARS-CoV-2 spike-specific CD4 + T cell response (at least one cytokine production), compared to 70% of SMM, 77.7 % of MMD and 58.3% of MMR patients (Fig. 3A) . In particular, we found that SMM, MMD and MMR had significantly reduced IL-2 + CD4 + T cells compared to MGUS patients, while we did not find any significant differences for IFN-γ-and TNF-α producing CD4 + T cells (Fig 3B) . Focusing on CD4 + T cells double positive, we found that MMR had significantly reduced IL-2+TNF-α+ CD4 + T cells compared to MGUS patients ( Fig 3C) .

Moreover, the percentages of patients with a SARS-CoV-2 spike-specific CD8 + T cell response were 100%, 80%, 55.5% and 91.6% among MGUS, SMM, MMD and MMR, respectively (Fig. 3A) . In particular, we found that MMD patients had a significant reduction in IFN-γ + CD8 + T cells compared to MGUS but any significant difference for TNF-α production ( Fig 3D) . Focusing on CD8 + T cells double positive, we found that both MMD and MMR patients had significantly reduced IFNγ + CD107a + CD8+ T cell responses compared to MGUS and MMD compared also to SMM patients All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in (Fig. 3E) . Moreover, MMD patients had significantly reduced TNF-α + CD107a + CD8 + T cells compared to MGUS (Fig.3E ).

Finally, we did not find a significant correlation between levels of spike-IgG-Abs and SARS-CoV-2specific CD4+ or CD8+ T cells (Suppl. Fig. 3 ).

Taken together, these data indicate that not only MM but also SMM patients showed a reduced cellular response to SARS-CoV-2 full vaccination compared to MGUS and a reduced percentage of antigen-specific IL-2 + CD4 + T cells. MM patients, concomitantly, showed a reduced cytotoxic function exerted by the IFN-γ + and TNF-α + CD8 + T cells, compared to MGUS.

In 16 MM patients of our cohort, 7 MMD and 9 MMR, we also evaluated the humoral and cellular spike-specific responses after a heterologous booster mRNA-1273 vaccine (Fig. 4A) , Firstly, MMR patients retained significantly lower anti-spike-IgG-Abs levels compared to MMD patients, even after the booster dose ( Fig 4B) .

Secondly, comparing spike-IgG-Abs levels between POST and BOOSTER, we did not find a significant increase both in MMD and MMR patients. However, after the booster dose, 85.7% (6/7) of MMD patients improved spike-IgG-Abs levels and among MMR patients, 50% (2/4) of the seronegative patients, in the POST sample, had a seroconversion and 60% of the seropositive patients (3/5) had an increase in spike-IgG-Abs levels. (Fig. 4C) Subsequently, we found a significant increase in the NAb titer to the Whuan-Hu-1 spike in MMD but not in MMR patients, although 6/9 (66.6%) MMR patients improved their titers respect the POST sample. (Fig.4D) .

Interestingly, the NAb titers against spike variants, including the Omicron one, significantly increased after the booster compared to the second dose in MMD patients (Fig. 4E) . Among MMR patients, we found a significant increase in the NAb titer to the Alpha, Gamma and Delta variants, but not to Beta and Omicron variants. (Fig. 4E) . However, 4/9 (44.4%) of MMR patients reached delectable levels All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Despite this last result, MMR patients retained significantly lower titers compared to MMD patients against the Whuan-Hu-1 spike and the five variants, even after the booster dose. (Fig. 4F, Finally, we explored the impact of the heterologous BOOSTER on the cellular responses. We noticed that CD4 + and CD8 + T cell responses to SARS-CoV-2 vaccine were highly variable in our cohort still after the booster dose (Fig. 5) .

We observed an increase in the percentage of MM patients with detectable SARS-CoV-2 spikespecific CD4+ T cells (at least one cytokine production) (100% of MMD and MMR patients) (Fig.   5A ). Notably, we found a significant increase in IL-2 + CD4 + T cells in the BOOSTER compared to the POST among MMD patients. MMR patients did not reach statistical significance as group, but 6/9 (66.6%) patients showed an increase in IL-2 + CD4 + T cells. Intriguingly, the 4 MMR patients, that reached delectable levels of NAbs against Omicron variant after BOOSTER, had a concomitant increase in the percentage of IL-2 + CD4 + T cells. In our cohort, we did not find any significant differences between BOOSTER and POST, in terms of IFN-γ + or TNF-α + CD4 + T cells (Fig. 5B) .

The percentages of patients with detectable SARS-CoV-2 spike-specific CD8 + T cell responses increased to 85.7% in MMD and, on the other hand, the percentages decreased to 55,5% in MMR patients (Fig. 5A) . In fact, we found a significant reduction in SARS-CoV-2 spike-specific IFNγ + CD8 + T cells in MMR patients in BOOSTER compared to POST samples (Fig. 5C) , while we did All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 26, 2022. ; https://doi.org/10.1101/2022.02.25.22271501 doi: medRxiv preprint not find any significant differences between BOOSTER and POST, in terms of IL-2 + or TNF-α + CD8 + T cells both in MMD and MMR patients. (Fig. 5C) Taken together, these data demonstrate that booster immunization improved SARS-CoV-2 spike humoral and cellular responses in MMD patients and in most, but not all, MMR patients. After the booster dose, a significant increase of the NAb titers against almost all the analyzed variants was achieved in MMD but in MMR patients Omicron retain a negative impact.

In this study, we performed a comprehensive analysis of immune responses after mRNA SARS-CoV-2 vaccination among a cohort of patients with monoclonal gammopathies at different stages of disease, that are known to show a impaired or reduced response to vaccination. 5 In addition, we also evaluated the impact of the different SARS-Cov-2 variants and the effect of booster dose on the immune response. Firstly, consistently with recent literature data, we found that MMR patients had significantly lower spike-IgG-Abs compared to the other groups of patients. 9, 10, 27 Considering pre-vaccination immune parameters, immunoparesis with the involvement of more than one class of Ig, the reduction of absolute number of CD4 + T cells and consequently a reduced CD4 + /CD8 + ratio may affect the production of spike-IgG-Abs after full vaccination. MM patients are known to have a deep reduction of CD4 + T cells with an inverted CD4 + /CD8 + ratio compared to precursors stages of the disease. 28 In fact, CD4 + T cells are closely associated with B cell differentiation into IgG-producing plasma cells and with the development of an adequate humoral immune response.

Only a fraction of the spike-IgG-Abs produced after vaccination are capable of neutralization, resulting in a blunted virus infection. We reported that anti-SARS-CoV-2 spike neutralizing titers for the original Wuhan-Hu-1 spike protein were strongly correlated with the spike IgG antibody levels.

In particular, MMR patients showed a reduced NAb titers compared to all the other groups of patients, especially to MGUS, as previously reported. 10 Several SARS-CoV-2 variants have emerged in the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in last year with an impact on vaccine efficacy 29 . Delta variant was dominating the pandemic at the time of vaccination of our patients, while the novel Omicron variant is currently dominating. 13 It is reported in healthy subjects a reduction of NAb titers for Beta and Delta variants and an highly resistance of Omicron variant against antibody-mediated neutralization after both homologous and heterologous vaccination. 14,30,31 Thus we have analyzed the susceptibility of five variants, including the Omicron one, to vaccine-induced antibody neutralization in our cohort of patients. In our study, after full vaccination, NAb titers against Omicron variant dramatically dropped compared to those against the original strain or the other four variants, with no MMR patients showing detectable levels of NAbs.

Interestingly, all the analyzed variants, remarkably the Omicron one, had a significant negative impact on the neutralizing ability of the vaccine-induced antibodies not only in MMD and MMR but also in SMM, suggesting that this last group of patients already had features of immune system impairment more similar to MMD that MGUS patients. On the other hand, MGUS patients showed a lower neutralizing ability only to the Beta and Omicron variants, as reported in general population. 15, 16, 31, 32 Although NAbs are likely to be crucial in vaccine-induced protection, precise correlation to immunity are not completely defined and recent evidence also suggests an important role for T cells. 23, 24, 33, 34 Until now, only two groups described variable results on the antigen-specific cellular responses in the MM setting. In fact, Aleman et al. 11 highlighted that fully vaccinated seronegative MM patients had a reduction in the percentage of spike-specific CD4 + T cells compared to the seropositive patients.

On the other hand, another study on MM patients showed a significant lower percentage of spikespecific CD8 + INF-γ + T cells in the seronegative group. 35 Our study explores the vaccine-induced cellular responses also in the premalignant monoclonal gammopathies and our data indicate that 100% of the MGUS patients mounted a SARS-CoV-2 spike-specific CD4 + and CD8 + T cell response while the responder patients percentages decreased in MMD, MMR, and also SMM groups. In particular, a significant reduction of IL-2 + CD4 + T cell percentage was described in MMD, MMR, and SMM compared to MGUS patients. It is reported that the development of antigen-specific IL-All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in On the other hand, MMR benefited from the booster dose, even if they maintained lower levels of spike-IgG-Abs and NAbs compared to MMD patients. In fact, a significant increase of NAb titers was observed against 3 out of 5 analyzed variants. A slightly increase was reported also against Omicron one, where almost half of MMR patient reach detectable levels of NAbs, but, overall, MMR patients retained an increased susceptibility to Beta, Delta and Omicron variants as reported after full vaccination.

Concerning the impact of the booster dose on antigen-specific T cells, interestingly, both MMD and MMR reached the 100% of responders in terms of SARS-CoV-2 spike-specific CD4 + T cells with an increased percentage of IL-2 + CD4 + T cells compared to full vaccination. After booster dose, SARS-CoV-2 spike-specific CD8 + T cells had a highly variable trend in MM patients and, notably, almost all MMR patients had undetectable percentage of SARS-CoV-2 spike-specific IFN-γ + CD8 + T cells.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in This effect could be related to a different kinetic and/or homing of these circulating CD8 + T cells, as reported after COVID-19 in natural infection. 38 Although our study analyzed a limited number of patients for each group of disease stage and it lacks healthy donors as controls, it is important to note that the groups are very homogenous for age and that all patients underwent the same vaccine administration scheme and blood collection time points, thus excluding potential bias related to age, vaccine type or timing of antigen-specific responses detection. A previous study 10 , exploring the production of NAbs in a large cohort of vaccinated patients with plasma cell neoplasms, reported that patients with MGUS did not have significant differences compared to healthy controls, suggesting that these patients could be considered proper controls of an optimal response to SARS-CoV-2 vaccination.

In conclusion, our study indicates that patients with monoclonal gammopathies share a different and variable cellular and humoral immunity to SARS-CoV-2 vaccination and a significant reduced response was reported in MM patients with relapsed or refractory disease that underwent to at least perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in and MMR (fuchsia ♦)) with lines showing the median with IQR. Dotted lines show the lower limit of detection. Significant difference was determined by two-tailed Mann-Whitney U tests with P values shown when P < 0.05 (*P < 0.05, **P < 0.01, ***P < 0.001). show the lower limit of detection at <0.01. Statistical analysis was performed using a paired, twotailed, nonparametric Wilcoxon test. P values shown when P < 0.05 (*P < 0.05, **P < 0.01).

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 26, 2022. ; https://doi.org/10.1101/2022.02.25.22271501 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

PI Nicola Giuliani) and by the Associazione Italiana contro Leucemie, Linfomi e Mielomi ONLUS, ParmAIL. Author contributions The study was

prepared the pseudoviruses and performed the neutralization assays supported by

I. processed the blood samples and collected sera and mononuclear cells

provide clinical data and enrolled the patients

wrote the manuscript with input from all authors

Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study

Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Impact of COVID-19 in patients with multiple myeloma based on a global data network

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma

Fifth-week immunogenicity and safety of anti-SARS

CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against Alpha and Delta variants in Multiple Myeloma patients

Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant

The Omicron variant is highly resistant against antibodymediated neutralization: Implications for control of the COVID-19 pandemic

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay. Vaccines (Basel)

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccineelicited antibodies

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Adaptive immunity to SARS-CoV-2 and COVID-19

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients

The biological and clinical significance of emerging SARS-CoV-2 variants

Homologous and Heterologous Covid-19 Booster Vaccinations

Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflicts with the subject matter or materials discussed in the manuscript apart from those disclosed.